

# BMJ Open The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales

Dave Marteau,<sup>1</sup> Rebecca McDonald,<sup>2</sup> Kamlesh Patel<sup>1</sup>

**To cite:** Marteau D, McDonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. *BMJ Open* 2015;5:e007629. doi:10.1136/bmjopen-2015-007629

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2015-007629>).

Received 9 January 2015  
Revised 30 March 2015  
Accepted 9 April 2015



CrossMark

<sup>1</sup>Health and Human Development, University of East London, London, UK

<sup>2</sup>Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

## Correspondence to

Dr Dave Marteau,  
d.m.marteau@sa.uel.ac.uk

## ABSTRACT

**Objective:** To examine the population-wide overdose risk emerging from the prescription of methadone and buprenorphine for opioid substitution treatment in England and Wales.

**Design:** Retrospective administrative data study.

**Setting:** National databases for England and Wales.

**Participants/cases:** Drug-related mortality data were drawn from the Office for National Statistics, and prescription data for methadone and buprenorphine were obtained from the National Health Service for the years 2007–2012. During this 6-year period, a total of 2366 methadone-related deaths and 52 buprenorphine-related deaths were registered, corresponding to 17 333 163 methadone and 2 602 374 buprenorphine prescriptions issued. The analysis encompassed poisoning deaths among members of the wider population of England and Wales who consumed, but were not prescribed these medications, in addition to patients prescribed methadone or buprenorphine.

**Main outcome measures:** Mortality risk: substance-specific overdose rate per 1000 prescriptions issued; relative risk ratio of methadone in relation to buprenorphine.

**Results:** During the years 2007–2012, the pooled overdose death rate was 0.137/1000 prescriptions of methadone, compared to 0.022/1000 prescriptions of buprenorphine (including buprenorphine-naloxone). The analysis generated a relative risk ratio of 6.23 (95% CI 4.79 to 8.10) of methadone in relation to buprenorphine. UK Borders Agency data were taken into consideration and revealed that only negligible amounts of methadone and buprenorphine were seized on entering UK territory between 2007 and 2012, suggesting domestic diversion.

**Conclusions:** Our analysis of the relative safety of buprenorphine and methadone for opioid substitution treatment reveals that buprenorphine is six times safer than methadone with regard to overdose risk among the general population. Clinicians should be aware of the increased risk of prescribing methadone, and tighter regulations are needed to prevent its diversion.

## INTRODUCTION

Opioid use constitutes a global public health problem, as heroin users experience

## Strengths and limitations of this study

- Study is the first relative risk study of methadone versus buprenorphine in England and Wales, and the second only national study globally.
- Study draws on a very large source of data, comprising more than 19 million prescriptions across 6 years.
- Study presents an evaluation of risk across a full drug-using culture.
- Data do not allow the identification of differences in severity of drug dependence between patients prescribed methadone and those prescribed buprenorphine.
- The data used are based on the number of prescription items issued rather than number of identified patients.

significantly elevated mortality rates.<sup>1</sup> In the UK, heroin and other opioids are the main contributor to drug-related deaths,<sup>2</sup> despite a much lower prevalence of use relative to other illicit drugs (eg, cocaine).<sup>3</sup>

The UK National Health Service (NHS) provides opioid-dependent users with access to methadone and buprenorphine as substitution therapy.<sup>4</sup> Methadone is a synthetic opioid receptor agonist, while buprenorphine is a mixed agonist-antagonist which is prescribed as either a single-ingredient tablet or in combined formulation with naloxone, a potent opioid antagonist that is added to deter patients from injection use.<sup>5</sup>

Opioid substitution treatment is the most effective intervention for opioid dependence.<sup>6–7</sup> It has been found to reduce the risk of drug-related death<sup>8–11</sup> as well as the incidence of criminal offending<sup>12</sup> and is associated with the relatively low HIV rate among injection drug users in England and Wales.<sup>13</sup>

While many randomised controlled trials have compared methadone and buprenorphine with regard to their effectiveness at retaining people in treatment, suppressing craving, and reducing illicit opioid use, less is known about their relative safety. In a

meta-analysis of 31 trials, only two studies tested the safety of methadone and buprenorphine, finding no significant difference in the rate of adverse events between the treatment samples.<sup>7</sup>

Similarly, the question of the relative safety of methadone and buprenorphine in the wider community, that is, among individuals not in receipt of a prescription and consuming diverted drugs, has received fairly little attention. This is surprising for at least two reasons: first, misuse of either drug can cause fatal overdose, particularly when consumed in combination with other central nervous system depressants;<sup>14–18</sup> second, the diversion of buprenorphine and particularly methadone to the illicit market for sale or exchange is a known problem in the UK and abroad.<sup>19 20</sup>

Recent attempts to address the problem of diversion in the UK, by the introduction of supervised consumption of buprenorphine and methadone at the dispensing pharmacy,<sup>21</sup> have led to a significant reduction in the rate of methadone deaths in relation to number of patients treated.<sup>22</sup> Nonetheless, it appears that the substantial majority of methadone overdoses occur in the general population. The risk represented by black-market methadone is illustrated by a UK-wide analysis of methadone-related deaths between 2009 and 2012.<sup>23–26</sup> Of the reported 1117 deaths that involved methadone alone or in combination with other drugs, only 36% occurred among individuals who were known to be receiving methadone treatment. This finding is consistent with previous reports from New South Wales (Australia) and Germany,<sup>27 28</sup> where at least half of methadone overdose deaths were the result of diversion. Over a 9-month period, the New South Wales study<sup>28</sup> also compared total overdose mortality rates (ie, in-treatment and diversion) related to buprenorphine and methadone, and found that methadone was associated with a fourfold risk of overdose.

To date, there has been only one published evaluation of the relative safety of buprenorphine and methadone in a national treatment setting. In a review of drug-related deaths in France between 1994 and 1998, Auriacombe *et al*<sup>29</sup> found that in relation to the number of patients receiving opioid substitution treatment, methadone was at least three times more lethal than buprenorphine in terms of overdose deaths among the French population as a whole (ie, among patients and the general public). In a follow-up study, Auriacombe *et al*<sup>30</sup> noted that opiate overdose deaths had declined substantially following the introduction of buprenorphine treatment, but due to the correlational nature of the data, causality cannot be inferred.

To the best of our knowledge, this study constitutes the first effort to assess the relative safety of buprenorphine and methadone in Britain. Using Office for National Statistics mortality data and National Health Service prescription data for England and Wales from the years 2007 to 2012, the current study aimed to examine the population-wide overdose risk emerging

from the prescription of methadone and buprenorphine for opioid substitution treatment.

## METHODOLOGY

### Ethics committee approval

Following National Research Ethics Service guidance, ethics committee approval was not sought for this study as all analyses encompassed non-confidential, non-attributable, de-identified data available via public databases.

### Identification of individual number of prescriptions

Total quantities of buprenorphine, buprenorphine-naloxone and methadone dispensed in England and Wales from 2007 to 2012 were drawn from two sources: the National Health Service (England), and National Health Service (Wales) Prescription Cost Analysis data reports. To exclude prescriptions for either detoxification or pain management, sublingual formulations of less than 2.0 mg of buprenorphine, and buprenorphine patches were not counted. Methadone linctus, a preparation prescribed for coughs, was also excluded. As they are prescribed almost exclusively for the treatment of severe pain rather than substance dependence, methadone tablets were also disregarded. The use of methadone to manage pain is far less common than for treatment drug dependence. For instance, in Wales, in the years 2010/2011, methadone tablets comprised <1% of all methadone prescriptions. This accords with a separate UK finding that 99.5% of methadone dispensed in Scotland in 2008/2009 was against prescriptions for the treatment of substance dependence.<sup>22</sup>

Buprenorphine and buprenorphine-naloxone prescriptions are often dispensed as a composite of two or more individual items. For example, a 10 mg prescription comprises one box of 8 mg tablets, and one box of 2 mg tablets. Each of these boxes is recorded on the database as an individual dispensed prescription, leading to double counting. As a remedial means to determining the actual number of patients treated with buprenorphine or buprenorphine-naloxone, a survey was conducted of the 29 principal NHS treatment services in England and Wales to establish mean daily doses prescribed to patients. Fourteen services responded (48%). Accumulated returns from the survey produced mean average doses of 10.6 mg per day for buprenorphine substitution treatment (dose range from 6.14 mg to 11.9 mg), and 9.3 mg per day for buprenorphine-naloxone substitution treatment (dose range from 6.0 mg to 10.55 mg). Across all the 6 years studied, the mean average dose for all buprenorphine prescriptions was 10.43 mg per day.

The average dose of methadone across the 6 years was 46.6 mg per day. The total quantities of each drug dispensed per annum were subdivided by these doses to yield the total numbers of individual prescriptions written each year. As it is the standard duration of a substitution treatment prescription form raised in England and Wales (FP10 MDA), all prescriptions of

buprenorphine, buprenorphine-naloxone and methadone were presumed to be of 14 days' duration.

### Identification of number of buprenorphine and/or methadone related deaths

Mortality data were drawn from the Office for National Statistics 'Deaths Related to Drug Poisoning in England and Wales' 2012 data set.<sup>31</sup> In calculating deaths related to methadone or buprenorphine, the cause of death was defined using the WHO International Classification of Diseases, Tenth Revision (ICD-10) codes. Deaths were included when the underlying cause was drug poisoning, with buprenorphine and/or methadone mentioned on the death certificate.

When both drugs were referenced on a death certificate, the death was included in the breakdown of both drugs. Deaths in England and Wales include non-residents. Figures were based on deaths registered in each calendar year.

### Identification of imported quantities of methadone and buprenorphine

To control for a potential confounding influence of illegally imported quantities of these drugs, the study incorporated UK Borders Agency data of Class A and Class C drugs seized while entering UK territory between 2006 and 2012.

### Analysis

Causes of death and prescriptions issued to the user were tabulated separately. These numbers were aggregated to produce an estimate of the total fatalities and prescriptions issued during the study period. A summary measure 'Buprenorphine-All' was created for combined prescriptions of buprenorphine and buprenorphine-

naloxone, as UK Office for National Statistics mortality records did not differentiate between these two formulations.

To compare the risk of fatal overdose represented by the two drugs, the total number of prescriptions for buprenorphine (including buprenorphine-naloxone) and methadone were divided by the number of fatal poisonings attributed to either drug to calculate the comparative risk of fatal poisoning for the whole population from use of either drug, expressed as a death rate per 1000 prescriptions.

Risk ratios and CI were calculated by means of standard formula using the open-source effect size calculator by Wilson.<sup>32</sup>

### RESULTS

There were 2366 deaths related to methadone poisoning and 57 deaths related to buprenorphine in England and Wales between 2007 and 2012 (see [table 1](#)).

Almost seven times more prescriptions were issued for methadone than for buprenorphine between 2007 and 2012: 17.3 million prescriptions for methadone compared to only 2.6 million for buprenorphine (including buprenorphine-naloxone; see [table 2](#)). Over that time, the proportion of buprenorphine (all) to methadone prescriptions increased from 14% in 2007 to 18% in 2012, with methadone prescriptions gradually decreasing, following a peak of 3.1 million prescriptions in 2010. By contrast, buprenorphine-naloxone and buprenorphine prescriptions continued to increase throughout, with buprenorphine-naloxone increasing from 0.4% of total prescriptions in 2007 to 2.6% in 2012 ([figure 1](#)).

Among the whole population of England and Wales, there were 0.137 methadone-related deaths per 1000 prescriptions of methadone and 0.022 buprenorphine-

**Table 1** Number of deaths related to drug poisoning where buprenorphine and/or methadone were mentioned on the death certificate by cause, England and Wales, 2007–2012

	2007	2008	2009	2010	2011	2012	Total
<b>Methadone</b>	<b>325</b>	<b>378</b>	<b>408</b>	<b>355</b>	<b>486</b>	<b>414</b>	<b>2366</b>
Accidental poisoning by drugs, medicaments and biological substances	149	202	242	215	427	342	1577
Assault by drugs, medicaments and biological substances	1	2	1	0	0	2	6
Intentional self-poisoning and poisoning of undetermined intent, by drugs, medicaments and biological substances	42	32	26	42	48	47	237
Mental and behavioural disorders due to drug use (excluding alcohol and tobacco)	133	142	139	98	11*	23	546
<b>Buprenorphine</b>	<b>8</b>	<b>9</b>	<b>9</b>	<b>7</b>	<b>14</b>	<b>10</b>	<b>57</b>
Accidental poisoning by drugs, medicaments and biological substances	2	4	8	5	12	8	31
Assault by drugs, medicaments and biological substances	0	0	0	0	0	0	0
Intentional self-poisoning and poisoning of undetermined intent, by drugs, medicaments and biological substances	1	2	1	0	2	1	6
Mental and behavioural disorders due to drug use (excluding alcohol and tobacco)	5	3	0	2	0	1	10

\*In January 2011 the Office for National Statistics introduced a new version of ICD-10 (v2010), which featured stricter criteria for recording under this category: <http://www.ons.gov.uk/ons/rel/subnational-health3/deaths-related-to-drug-poisoning/2011/index.html>.

Source: Office for National Statistics.

ICD-10, International Classification of Diseases, Tenth Revision.

**Table 2** Prescriptions issued in England and Wales for opioid substitution treatment

Year	Buprenorphine-naloxone	Buprenorphine HCL	Buprenorphine All	Methadone
2007	12 295	344 703	356 998	2 513 076
2008	34 585	352 486	387 071	2 779 327
2009	64 736	371 327	436 063	3 017 531
2010	74 876	377 628	452 504	3 152 889
2011	79 215	387 357	466 572	3 025 956
2012	85 556	417 610	503 166	2 844 384
Total	<b>351 263</b>	<b>2 251 111</b>	<b>2 602 374</b>	<b>17 333 163</b>

HCL, hydrochloride.

Bold was used simply to indicate headings, sub-total and totals.


related deaths per 1000 prescriptions of buprenorphine-based drugs for the substitution treatment of opioid dependence (see [table 3](#)).

In terms of a fatality among the population of England and Wales as a whole, methadone represented a risk six times that of buprenorphine (RR 6.23; 95% CI (4.79 to 8.10)) ([figure 2](#)).

### Could the methadone or buprenorphine involved in these deaths have come from other countries?

Changes in the way in which seizures are recorded by the UK's customs authority (the UK Borders Agency) implies that no methadone data are available for years 2010/2011 and 2011/2012 (methadone seizures were incorporated within the 'Other class A' return and cannot be identified individually, see [table 4](#)). Reporting in preceding years (2006/2007–2009/2010) indicates a very low quantity of methadone entering into UK territory.

According to UK Borders Agency reports, no buprenorphine was seized by UK customs in either 2006/2007 or 2007/2008.<sup>33</sup> Buprenorphine was incorporated within the 'Other class C' returns from year 2008/2009; therefore, no seizure data were available for the remaining period of this study. In the 4 years that span 2006/2007 and 2009/2010 there were a total of 19 seizures of methadone by UK customs. In none of these years did the total quantity of



**Figure 1** Total prescriptions issued in England and Wales for opioid substitution treatment.

methadone seized by the UK Border Agency amount to 1000 doses. The total number of doses of methadone seized, therefore, amounted to less than 4000, while the average annual number of methadone and buprenorphine doses prescribed in England and Wales, over the same 4 year period (2006–2007 to 2009–2010), exceeded 38 million and 3.8 million doses, respectively. There have been no reports of detection of any illegal manufacture of methadone or buprenorphine in the UK throughout the period of this study.<sup>33</sup>

## DISCUSSION

### Statement of principal findings

Dose for dose, methadone was found to present a significantly greater risk of fatal overdose to the wider population than buprenorphine. Our finding is based on national administrative data collected in England and Wales between 2007 and 2012, and is consistent with the only published national study of this type.<sup>29</sup> Further, our finding is supported by a study from New South Wales<sup>28</sup> which reported a fourfold risk of overdose associated with methadone relative to buprenorphine.

During the 6-year period analysed in the present study, a very minor amount of imported methadone or buprenorphine was seized by UK customs, representing only a small fraction of prescriptions: per every dose seized by UK customs, roughly 10 000 prescriptions for methadone or buprenorphine were issued. Based on this ratio, the authors assume that illicitly imported methadone or buprenorphine were most likely not involved in the overdose deaths studied.

### Strengths and weaknesses of the study

The high number of people enrolled in opioid substitute treatment in England and Wales during the 6-year study period (approximately 766 000 patients) is considerably larger than the sample of 140 140 cases analysed in the French investigation by Auriacombe *et al.*<sup>29</sup> This allowed for a greater degree of confidence in calculating the relative risk (RR) of fatal overdose emerging from methadone and buprenorphine use.

Moreover, customs data were taken into consideration to control for illegal import of buprenorphine and methadone into the UK.



**Table 3** Methadone and buprenorphine-related death rate per 1000 prescriptions issued

Year	Buprenorphine		Methadone		Relative risk	CI (95%)
	Deaths	per 1000 R	Deaths	per 1000 R		
2007	8	0.022	325	0.129	5.77	2.86 to 11.64
2008	9	0.023	378	0.136	5.85	3.02 to 11.33
2009	9	0.021	408	0.135	6.55	3.38 to 12.68
2010	7	0.015	355	0.113	7.28	3.44 to 15.38
2011	14	0.030	486	0.161	5.35	3.15 to 9.11
2012	10	0.020	414	0.146	7.32	3.91 to 13.71
Total	<b>57</b>	<b>0.022</b>	<b>2366</b>	<b>0.137</b>	<b>6.23</b>	<b>4.79 to 8.10</b>

R=prescriptions.

The collation of data at the prescription item level (rather than numbers of patients treated) meant that the number of buprenorphine prescriptions had to be calculated on the basis of mean doses. However, the mean buprenorphine dose identified in this study (10.43 mg per day) is broadly consistent with the pooled average dose of 11.96 mg per day, as generated by seven published flexible-dose trials of buprenorphine with doses ranging from 8.9 mg to 12.7 mg.<sup>34–40</sup>

#### Meaning of the study: possible explanations and implications for clinicians and policymakers

The inclusion of UK customs data revealed that only negligible amounts of methadone and buprenorphine were seized during the study period, implying that illicitly imported methadone or buprenorphine are unlikely to be risk factors for overdose in England and Wales.

This finding points to domestic diversion as the probable source of black-market methadone and buprenorphine implicated in the overdose deaths of individuals not in treatment.

Like other areas of medical research, the evaluation of opioid substitution therapy has traditionally focused on assessing the impact of treatment on clinical outcomes within treatment cohorts. However, our findings suggest that the degree of diversion of prescribed opioid

substitutes<sup>19 25 26 41</sup> and associated overdose risk in the wider population should also be taken into consideration.


Neither methadone nor buprenorphine are free from risk, not lastly because of potentially hazardous interactions when taken together with other central nervous system depressants (eg, benzodiazepines, alcohol),<sup>18</sup> but our results demonstrate that for the years 2007–2012 buprenorphine was significantly safer for the population of England and Wales.

In appraising the cost-effectiveness of the methadone and buprenorphine, the National Institute for Health & Care Excellence<sup>4</sup> recommends that “[t]he decision about which drug to use should be made on a case by case basis, taking into account a number of factors, including the person’s history of opioid dependence, their commitment to a particular long-term management strategy, and an estimate of the risks and benefits of each treatment made by the responsible clinician in consultation with the person. If both drugs are equally suitable, methadone should be prescribed as the first choice”.

While taking full account of the limitations identified in the preceding section, this study identifies a substantial RR differential between methadone and buprenorphine. Our finding, together with previous UK<sup>25 26</sup> and international reports<sup>27 28 30</sup> of overdose fatalities linked to methadone diversion, suggests that the treatment sector may need to reappraise its relationship with methadone.

Generally, opioid substitution treatment in the UK begins under a regime of supervised consumption in a community pharmacy, but weekend and bank holiday closures mean that from the outset many patients are trusted to take home up to 2 or 3 days’ prescription. UK clinical guidelines<sup>42</sup> suggest that supervised consumption can be relaxed and take-home doses prescribed when a doctor has good reason to believe that a patient will be able to maintain compliance with his or her methadone treatment.

The risk of methadone diversion into the black market makes it apparent that this can be an extremely difficult judgement for a clinician to make regarding the potential safety implications for persons other than the individual patient.



**Figure 2** Methadone and buprenorphine-related death rate per 1000 prescriptions.

**Table 4** Number of UK customs drug seizures by class, drug type and year (class A and C only)

	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012
<b>Class A</b>						
Cocaine	1141	1254	1024	1026	837	767
Heroin	64	68	171	108	110	117
Methadone	<b>3</b>	<b>4</b>	<b>4</b>	<b>8</b>	*	*
Other class A	264	192	141	104	342	231
All class A	<b>1456</b>	<b>1508</b>	<b>1319</b>	<b>1235</b>	<b>1287</b>	<b>1115</b>
<b>Class C</b>						
Anabolic steroids	89	126	259	341	113	133
Benzodiazepines	950	1484	2539	870	†	†
Buprenorphine	0	0	†	†	†	†
Other class C	124	143	309	121	975	729
All class C	<b>1163</b>	<b>1753</b>	<b>3107</b>	<b>1332</b>	<b>1088</b>	<b>862</b>

\*Data unavailable, incorporated within 'Other class A' figure.

†Data unavailable, incorporated within 'Other class C' figure.

Source: Home Office, England and Wales, 2012.

To conclude, for clinicians and policymakers alike, both risk of diversion and the significant RR differential between methadone and buprenorphine, as identified in this study, should form part of individual treatment decisions as well as treatment guidelines.

### Unanswered questions and future research

Buprenorphine-naloxone shows early promise of increased safety over single-ingredient buprenorphine,<sup>43</sup> but there are also indications that its self-injection can represent a comparable risk of death to the single-agent formulation.<sup>44</sup> The short half-life of naloxone relative to buprenorphine may mean that the intoxicating effect of the buprenorphine is sometimes merely delayed rather than eliminated following injected use.<sup>44</sup> There are insufficient data within this evaluation to draw any conclusion on the question of the comparative safety of buprenorphine-naloxone versus single-ingredient buprenorphine; this should be addressed by future studies.

An Australian study<sup>36</sup> reported an indication of increased risk of mortality among patients following the cessation of buprenorphine treatment. Measurement of mortality following the cessation of treatment by either buprenorphine or methadone is beyond the scope of this study and would be a valuable subject for future research.

The study could not establish if there were differences in severity of dependence between the two patients groups (ie, those prescribed methadone and those prescribed buprenorphine). The feasibility of increasing the use of buprenorphine over methadone in the prescribed management of opioid dependence is, therefore, beyond the scope of this study.

**Twitter** Follow Dave Marteau at @dmar

**Contributors** DM and KP conceived the study. DM carried out the database analyses and wrote the initial elements of the article, which KP helped edit. RM wrote further elements of the article, calculated each of the risk ratios and added text to complete the work.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Technical appendix and the data set are available from the corresponding author at d.m.marteau@sa.uel.ac.uk

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

### REFERENCES

- Degenhardt L, Bucello C, Mathers B, *et al*. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. *Addiction* 2011;106:32–51.
- ACMD. *Consideration of Naloxone*. London: Home Office. London, England: The Stationery Office, 2012.
- Office H. Drug Strategy 2010. Reducing Demand, Restricting Supply, Building Recovery: Supporting People to Live a Drug-free Life 2010 [30 May 2014]. [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/118336/drug-strategy-2010.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/118336/drug-strategy-2010.pdf)
- (NICE) NifHCE. NICE technology appraisal guidance 114, Methadone and buprenorphine for the management of opioid dependence, 2007 [25 April 2014]. <http://www.nice.org.uk/TA114>
- Wesson DR. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. *J Psychoactive Drugs* 2004;(Suppl 2):119–28.
- Mattick RP, Breen C, Kimber J, *et al*. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009, Issue 3: CD002209. doi:10.1002/14651858.CD002209.pub2. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002209.pub2/pdf>
- Mattick RP, Kimber J, Breen C, *et al*. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev* 2014;2(2): CD002207. doi:10.1002/14651858.CD002207.pub4. <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002207.pub4/pdf>
- Cornish R, Macleod J, Strang J, *et al*. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *BMJ* 2010;341.
- Kimber J, Copeland L, Hickman M, *et al*. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. *BMJ* 2010;341:c3172.
- Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. *Drug Alcohol Depend* 2008;94:151–7.
- Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. *Acta Psychiatr Scand* 1990;82:223–7.

12. Dolan KA, Shearer J, White B, *et al.* Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. *Addiction* 2005;100:820–8.
13. (UKDP) UDPC. An Analysis of UK Drug Policy 2007 [May 30 2014]. <http://www.ukdpc.org.uk/publication/an-analysis-uk-drug-policy/>
14. Coffin PO, Galea S, Ahern J, *et al.* Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. *Addiction* 2003;98:739–47.
15. Hickman M, Carrivick S, Paterson S, *et al.* London audit of drug-related overdose deaths: characteristics and typology, and implications for prevention and monitoring. *Addiction* 2007;102:317–23.
16. Kintz P. A new series of 13 buprenorphine-related deaths. *Clin Biochem* 2002;35:513–16.
17. Schifano F, Corkery J, Gilvarry E, *et al.* Buprenorphine mortality, seizures and prescription data in the UK, 1980–2002. *Hum Psychopharmacol* 2005;20:343–8.
18. Hakkinen M, Launiainen T, Vuori E, *et al.* Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. *Eur J Clin Pharmacol* 2012;68:301–9.
19. Duffy P, Baldwin H. The nature of methadone diversion in England: a Merseyside case study. *Harm Reduct J* 2012;9:3.
20. Yokell MA, Green TC, Bowman S, *et al.* Opioid overdose prevention and naloxone distribution in Rhode Island. *Med Health R I* 2011;94:240.
21. Hickman M, Madden P, Henry J, *et al.* Trends in drug overdose deaths in England and Wales 1993–98: methadone does not kill more people than heroin. *Addiction* 2003;98:419–25.
22. Strang J, Hall W, Hickman M, *et al.* Impact of supervision of methadone consumption on deaths related to methadone overdose (1993–2008): analyses using OD4 index in England and Scotland. *BMJ* 2010;341:c4851.
23. Corkery J, Claridge H, Loi B, *et al.* *Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), UK Annual Report 2012*. London: St George's University, 2013.
24. Ghodse H, Corkery J, Claridge H, *et al.* *Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), UK Annual Report 2011*. London: St George's University, 2012.
25. Ghodse H, Corkery J, Ahmed K, *et al.* *Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), UK Annual Report 2010*. London: St George's University, 2011.
26. Ghodse H, Corkery J, Oyefeso A, *et al.* *Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), International Centre for Drug Policy (ICDP), UK Annual Report 2009*. London: St George's University, 2010.
27. Heinemann A, Iwersen-Bergmann S, Stein S, *et al.* Methadone-related fatalities in Hamburg 1990–1999: implications for quality standards in maintenance treatment? *Forensic Sci Int* 2000;113:449–55.
28. Bell JR, Butler B, Lawrance A, *et al.* Comparing overdose mortality associated with methadone and buprenorphine treatment. *Drug Alcohol Depend* 2009;104:73–7.
29. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. *JAMA* 2001;285:45.
30. Auriacombe M, Fatseas M, Dubernet J, *et al.* French field experience with buprenorphine. *Am J Addict* 2004;13(Suppl 1): S17–28.
31. ONS. Statistical bulletin: Deaths related to drug poisoning in England and Wales, 2012, 2013 [May 30, 2014]. <http://www.ons.gov.uk/ons/rel/subnational-health3/deaths-related-to-drug-poisoning/2012/stb---deaths-related-to-drug-poisoning-2012.html>
32. Wilson DB. Practical Meta-Analysis Effect Size Calculator 2014 [June 31, 2014]. [http://www.campbellcollaboration.org/resources/effect\\_size\\_input.php](http://www.campbellcollaboration.org/resources/effect_size_input.php)
33. Office H. *Seizures of Drugs in England and Wales, 2011/12, Second Edition*. London: Home Office, 2012.
34. Curcio F, Franco T, Topa M, *et al.* Gruppo Responsabili UOST. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. *Eur Rev Med Pharmacol Sci* 2011;15:871–4.
35. Neri S, Bruno CM, Pulvirenti D, *et al.* Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. *Psychopharmacology (Berl)* 2005;179:700–4.
36. Lintzeris N, Ritter A, Panjari M, *et al.* Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. *Am J Addict* 2004;13(Suppl 1): S29–41.
37. Mattick RP, Ali R, White JM, *et al.* Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. *Addiction* 2003;98:441–52.
38. Petitjean S, Stohler R, Deglon JJ, *et al.* Double-blind randomized trial of buprenorphine and methadone in opiate dependence. *Drug Alcohol Depend* 2001;62:97–104.
39. Strain EC, Stitzer ML, Liebson IA, *et al.* Comparison of buprenorphine and methadone in the treatment of opioid dependence. *Am J Psychiatry* 1994;151:1025–30.
40. Strain EC, Stitzer ML, Liebson IA, *et al.* Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. *Psychopharmacology (Berl)* 1994;116:401–6.
41. Yokell MA, Zaller ND, Green TC, *et al.* Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. *Current Drug Abuse Rev* 2011;4:28–41.
42. administrations DoHEatd. *Drug misuse and dependence: UK guidelines on clinical management*. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, 2007.
43. Dart R. Buprenorphine. College on Problems of Drug Dependence, 74th Annual Scientific Meeting. Palm Springs, California, 2012.
44. Hakkinen M, Heikman P, Ojanpera I. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning. *Forensic Sci Int* 2013;232:11–15.